Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)

NCT07102511 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.

NCT NCT07102511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)
Lead sponsor
LIB Therapeutics LLC
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
July 20, 2026
Completion date
November 30, 2028
Enrollment
150 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

familial hypercholesterolemia - heterozygous